Xilio Therapeutics Appoints Yuan Xu, Ph.D., to Board of Directors

Xilio Therapeutics, Inc.

Board expanded from 8 to 9 directors; Dr. Xu appointed as Class II director effective Jan 4, 2022.
Dr. Xu is former CEO of Legend Biotech and held senior roles at Merck, Gilead, Novartis.
Her appointment comes as Xilio expects initial data readouts for XTX101 and XTX202 in 2022.
Dr. Xu will receive standard non-employee director compensation and enter indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yuan Xu

Director

XLO · Xilio Therapeutics, Inc.

Effective: 2022-01-04
Filed: January 6, 2022, 6:59 PM ET

Effective January 4, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Yuan Xu, Ph.D. to fill a newly created vacancy on the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yuan Xu was appointed as Director at Xilio Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective January 4, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Yuan Xu, Ph.D. to fill a newly created vacancy on the Board

View on SEC.gov

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-000083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.